EP1296668A2 - Compositions a base d'aminoacides permettant d'ameliorer les performances musculaires - Google Patents

Compositions a base d'aminoacides permettant d'ameliorer les performances musculaires

Info

Publication number
EP1296668A2
EP1296668A2 EP01940936A EP01940936A EP1296668A2 EP 1296668 A2 EP1296668 A2 EP 1296668A2 EP 01940936 A EP01940936 A EP 01940936A EP 01940936 A EP01940936 A EP 01940936A EP 1296668 A2 EP1296668 A2 EP 1296668A2
Authority
EP
European Patent Office
Prior art keywords
amino acids
compositions
previous
active ingredients
threonine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01940936A
Other languages
German (de)
English (en)
Inventor
Francesco Saverio Dioguardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Professional Dietetics SpA
Original Assignee
Professional Dietetics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics SpA filed Critical Professional Dietetics SpA
Publication of EP1296668A2 publication Critical patent/EP1296668A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention refers to compositions based on amino acids, in particular for oral or parenteral use, suitable for improving muscle performance, particularly but not exclusively in patients suffering of heart insufficiencies.
  • CHF chronic heart failure
  • National statistics indicate that, in the USA, chronic heart failure (CHF) incidence and prevalence have increased over the last twenty years, despite the increased resources devoted to its prevention (Sytkowski P.A. et al.; New England Journal of Medicine, 1990; 322: 1635-1641), and the significant progresses in availability of treatment of this particular disease (Pitt B. et al.; New England Journal of Medicine, 1999; 341 : 709-717).
  • Chronic heart failure is no longer strictly deemed as the consequence of hypertension or valvular heart disease, but rather of coronary heart disease, and therefore of arteriosclerosis (Gheorghiade M. and Bonow R.O.; Circulation, 1998; 97: 282-289).
  • intolerance to physical exercise is one of the major clinical feature, which is consistent with the proceeding of the same pathology; in addition, a noticeable skeletal muscle atrophy, often in the absence of signs of severe malnutrition, is a quite constant accompanying feature of chronic heart failure of any grade (Mancini D.M. et al.; Circulation, 1992, 85: 1364- 1373).
  • Mechanisms of muscle wasting have been recently reviewed in literature (Mitch W.E. and Goldberg A.L.; New England Journal of Medicine, 1996; 355: 1897- 1905).
  • the present invention has the aim of indicating compositions which are capable of determining a noticeable improvement in muscle performances, particularly but not exclusively in patients suffering of heart insufficiencies.
  • a further aim of the invention is that of indicating an absolutely innovative therapeutic approach to the problem of heart insufficiency.
  • compositions being in particular provided for oral or parenteral use, are characterized by comprising, as main active ingredients, the branched chain amino acids leucine, isoleucine and valine, up to 75% of all the amino acids or active ingredients being present, by expressing the value in molecular weights.
  • the compositions according to the invention also comprise, as further active ingredients, threonine and lysine, where in particular threonine plus lysine are present up to 50% of all the amino acids or active ingredients being present, by expressing the value in molecular weights.
  • compositions can provide, as further active ingredients, other essential amino acids, in particular methionine and/or phenylalanine ⁇ and/or histidine and/or triphtophan, and non essential amino acids, in particular tyrosine and/or cyst(e)ine (i.e. cystine and cysteine).
  • other essential amino acids in particular methionine and/or phenylalanine ⁇ and/or histidine and/or triphtophan
  • non essential amino acids in particular tyrosine and/or cyst(e)ine (i.e. cystine and cysteine).
  • the sum of the amounts being expressed in molecular weights of threonine and lysine is greater than the sum of the single amounts of the other essential amino acids being provided, but in any case lower than the sum of the single amounts of the branched chain amino acids being provided.
  • the amounts being expressed in molecular weight of threonine and of lysine can be each greater than the single amounts of the other essential amino acids being provided, but in any case lower than the single quantities of the branched chain amino acids being provided.
  • compositions according to the, invention can also comprise one or more further amino acids, with respect to those as previously indicated, the sum of which, expressed in molecular weight, is preferably lower than 20% with respect to the active ingredients, and less than 10% for each single further amino acid.
  • a mixture of amino acids particularly suitable for nutritional use in humans should satisfy different requirements: - the content of essential amino acids in the mixture should be in an adequate ratio to fulfill real human nutritional needs (and this can be optimized by the co-operative adjunction of adequate and small ratios of some non essential amino acids); the pH of the solution of the mixture should be substantially neutral, in order to prevent urinary calcium losses; the mixture should be safe, in respect to calcium balance (i.e.: with no urinary losses) and homocyst(e)ine production (i.e., preferably related to the amount of all amino acids, a strictly correct ratio of sulphur containing amino acids, with a ratio cyst(e)ine / methionine of at least 2: 1 on a sto
  • composition according to the invention comprising essential amino acids (leucine, isoleucine, valine, threonine, lysine, methionine, phenylalanine, histidine, triphtophan) and some non essential amino acids (tyrosine and cyst(e)ine), in different but fixed and co-operative molar ratios among them, is the following one: branched chain amino acids leucine (40-60% in molecular weight), isoleucine (20-40% in molecular weight) and valine (20-40% in molecular weight), preferentially in a stoichiometric ratio 2:1 :1 among them, covering from 30 to
  • threonine plus lysine preferably in a w/w molar ratio with the above said branched chain amino acids between 20 and 50%, but with a threonine to lysine ratio in which threonine is from 10 to 50% more represented than lysine; the above said branched chain amino acids plus threonine and lysine, whose sum of the molecular weight is in a stoichiometric ratio of 50 to 70% of a mixture also comprising histidine and other amino acids, were histidine is present in molar ratio up to 50% of the following amino acids: - cyst(e)ine (i.e., cystine and cysteine) and methionine, up to 50% of histidine (the ratio between cyst(e)ine and methionine should be preferably of 50 to 200% greater for cyst(e)ine on a w/w molar ratio), phenylalanine and tyrosine, in m
  • any other amino acid can be summed to the above formulation, without altering the expected effects, if their sum would be in a percentage lower than 20% with respect to the other active ingredients (less that
  • a significant characteristic of the above said formulation is that of having a pH in water solution comprised between 6.5 and 8.5, and therefore suitable for a safe oral or parenteral use, in humans or animals, according to needs. This feature prevents the excessive calcium urinary losses induced by protein sources of amino acids.
  • the effects on energy balance of the an amino acids mixture according to the invention as above indicated were the subject of a comparative study with creatine, on a weight ratio (w/w), or with no treatment, on a large group of volunteers submitted to a rigid protocol of alimentation and training.
  • Table 1 which follows shows the result of such a study , were the effect of the amino acids mixture according to the invention (24 g/d "1 ), creatine (25 g/d "1 ) and placebo have been compared to each other, after one month of and homogeneous treatment and training, in groups of athletes were:
  • Group 1 is the group treated with the mixture according to the invention.
  • Tables 2 shows in particular the modifications induced by chronic administration of the amino acids mixture according to the invention in normal athletes (healthy).
  • FC Cardiac frequency
  • Watt peak power production
  • Cysteine 3 ⁇ 1 4 ⁇ 3 Cardiac cachexia (the severe muscle wasting observed even in absence of malnutrition in chronic heart insufficiency patients), is a quite constant and noxious condition, clinically associated to chronic heart failure and potentially life threatening (Anker S.D. et al.; Lancet, 1997; 349:1050-1053).
  • Table 4 plasma profiles are reported of amino acids as they can be detected in healthy athletes (weight lifters), that underwent to leg strenuous exercise (i.e., leading to exhaustion) for 45 minutes, after an overnight fasting.
  • fuel availability is the main control of the origin of energy from one or another substrate.
  • citric acid cycle the main energy producer of any body cell
  • citric acid cycle the main energy producer of any body cell
  • acetyl groups and intermediates of the said cycle mostly at committed steps as ⁇ -ketoglutarate and succinate
  • oxaloacetate-citrate The part of them not utilized for energy production is exported to cytoplasm as malonylCoA-malate or glutamic acid-glutamine, via mitochondria co-transporter systems.
  • this peculiar metabolic flow will inhibit pyruvate dehydrogenase, by activation of pyruvate dehydrogenase kinase in presence of acetylcoA and NADH, avoiding pyruvate from lipid syntheses.
  • compositions according to the invention are particularly efficacious for improving the muscle performances, particularly but not exclusively in patients suffering of chronic heart failure patients. From the above, it is also clear that the compositions according to the invention are particularly efficacious also for treating chronic heart failure. Within these frames, the compositions according to the invention are particularly efficacious:
  • compositions according to the invention are suitable for being added to and/or improving clinical effects of any other therapeutic schedule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions à base d'aminoacides, en particulier pour l'utilisation orale ou parentérale permettant d'améliorer les performances musculaires. Les compositions décrites par la présente invention sont composées, jusqu'à 75 % des amino-acides à chaîne ramifiée suivants, la leucine, l'isoleucine et la valine comme ingrédients actifs. Ces compositions comprennent également, de préférence, comme ingrédients actifs supplémentaires jusqu'à 50 % de thréonine et de lysine. D'autres aminoacides essentiels sont présents de préférence (en particulier, la méthionine, la phénylalanine, l'histidine, le tryptophane) ainsi que des aminoacides non-essentiels (en particulier, la tyrosine et/ou la cyst(é)ine, par exemple, la cystine et la cyst(é)ine). D'autres aminoacides peuvent également être ajoutés à condition que leur somme représente un pourcentage inférieur à 20 % par rapport aux autres ingrédients actifs et inférieur à 10 % pour chaque aminoacide seul.
EP01940936A 2000-07-04 2001-06-28 Compositions a base d'aminoacides permettant d'ameliorer les performances musculaires Withdrawn EP1296668A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO000675 2000-07-04
IT2000TO000675A IT1320783B1 (it) 2000-07-04 2000-07-04 Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
PCT/IB2001/001182 WO2002002092A2 (fr) 2000-07-04 2001-06-28 Compositions a base d'aminoacides permettant d'ameliorer les performances musculaires

Publications (1)

Publication Number Publication Date
EP1296668A2 true EP1296668A2 (fr) 2003-04-02

Family

ID=11457894

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01940936A Withdrawn EP1296668A2 (fr) 2000-07-04 2001-06-28 Compositions a base d'aminoacides permettant d'ameliorer les performances musculaires

Country Status (4)

Country Link
EP (1) EP1296668A2 (fr)
AU (1) AU2001274422A1 (fr)
IT (1) IT1320783B1 (fr)
WO (1) WO2002002092A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20010580A1 (it) * 2001-06-15 2002-12-15 Professional Dietetics Srl Composizioni a base di aminoacidi per il miglioramento della funzioneventricolare miocardica in pazienti affetti da diabete.
GB2394698A (en) 2002-11-01 2004-05-05 Gibbs Tech Ltd Amphibious vehicle wheel transmission arrangement
IT1397023B1 (it) * 2009-11-27 2012-12-20 Professional Dietetics Srl Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
IT1397446B1 (it) * 2010-01-12 2013-01-10 Professional Dietetics Srl Compositions comprising amino acids for prevention and/or treatment of renal disorders.
DK3006027T3 (en) * 2014-10-08 2017-12-18 Professional Dietetics Spa Compositions comprising amino acids for use in the treatment of systemic inflammation associated with stroke in dysphagia patients
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
PE20200747A1 (es) 2017-08-14 2020-07-24 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
IT202000021664A1 (it) * 2020-09-14 2022-03-14 Iaf Network S P A Formulazione amminoacidica bilanciata

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276018A (en) * 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
IT1289754B1 (it) * 1996-12-16 1998-10-16 Professional Dietetics Srl Composizioni a base di aminoacidi

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO0202092A3 *

Also Published As

Publication number Publication date
ITTO20000675A0 (it) 2000-07-04
IT1320783B1 (it) 2003-12-10
AU2001274422A1 (en) 2002-01-14
WO2002002092A2 (fr) 2002-01-10
ITTO20000675A1 (it) 2002-01-04
WO2002002092A3 (fr) 2002-06-20

Similar Documents

Publication Publication Date Title
US8536216B2 (en) Compositions based on aminoacids
US5817329A (en) Nutritional supplement for increased muscle size and strength for body builders
Van Hall et al. Ingestion of branched‐chain amino acids and tryptophan during sustained exercise in man: failure to affect performance.
Mero Leucine supplementation and intensive training
CA2334415C (fr) Compositions permettant d'accroitre l'energie in vivo
Aquilani et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure
US7850997B2 (en) Dietary compositions and methods of enhancing lean body mass and exercise performance
US20020072501A1 (en) Compostitions for increasing energy in vivo
Sole et al. Conditioned nutritional requirements: therapeutic relevance to heart failure
US20100280123A1 (en) Food supplement containing alpha-keto acids for supporting diabetes therapy
EP1296668A2 (fr) Compositions a base d'aminoacides permettant d'ameliorer les performances musculaires
US20030187049A1 (en) Compositions based on aminoacids, suitable for improving muscle performance
JP2002512191A (ja) Ｌ−カルニチンまたはアルカノイルｌ−カルニチンおよびｎａｄｈおよび／またはｈａｄｐｈを含む組成物。
CA2285490C (fr) Composition pour ameliorer la nutrition des cellules et la capacite energetique des mitochondries
FR2710243A1 (fr) Composition énergétique à base d'acides aminés à chaîne ramifiée.
JP2019505593A (ja) ミトコンドリア機能を改善するための組成物及び方法
Argiles et al. Branched-chain amino acid catabolism and cancer cachexia
Heath Niacin
US20070117867A1 (en) Kit comprising three independent compositions and methods for building muscle, increasing strength, increasing muscle size, increasing muscle performance and reducing muscle fatigue
WO2023016852A1 (fr) Composition d'acides aminés en tant qu'agent vasodilatateur
WO2008037047A1 (fr) Composition et procédé pour l'accroissement de la masse musculaire maigre, la réduction de perte musculaire, l'accroissement de la force musculaire et l'amélioration de la performance athlétique
Wurst Role of Amino Acid Ingestion in Protein Synthesis, Muscular Recovery and Adaptation to Exercise Training
Petric Thesis: Levodopa as pre-prodrug
Lee et al. b-hydroxy-b-methylbutyrate (HMB) Improves Relative Grip Strength and Sensorimotor Function in Middle aged and Old Rats: 2856: Board# 207 June 4 3: 30 PM-5: 00 PM
Zhang et al. The Effect of Silk Amino Acid Supplementation on the Level of Blood Energy Substrates and Hormones during Prolonged Exercise

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030120

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20030904

17Q First examination report despatched

Effective date: 20030904

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070605